StockData
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. (APRE) stock

APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$0.45+0.05 (+11.52%)

Close on Nov 17, 2026Market cap $5.71MP/E –Yield –

Aprea Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Aprea Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.72M, down 30.0% year over year. For fiscal 2025 it was $7.04M, down 24.8% from the year before. The highest annual figure on record is $37.88M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.04M-24.8%
FY2024Dec 31, 2024$9.36M+22.8%
FY2023Dec 31, 2023$7.63M-53.5%
FY2022Dec 31, 2022$16.40M-31.4%
FY2021Dec 31, 2021$23.90M-36.9%
FY2020Dec 31, 2020$37.88M+80.8%
FY2019Dec 31, 2019$20.95M+47.6%
FY2018Dec 31, 2018$14.19M+6.0%
FY2017Dec 31, 2017$13.39M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.46M+28.8%
Q1 FY2026Mar 31, 2026$1.61M-35.1%
Q4 FY2025Dec 31, 2025$1.01M-57.2%
Q3 FY2025Sep 30, 2025$1.64M-42.4%
Q2 FY2025Jun 30, 2025$1.91M-25.2%
Q1 FY2025Mar 31, 2025$2.48M+55.2%
Q4 FY2024Dec 31, 2024$2.36M+15.3%
Q3 FY2024Sep 30, 2024$2.85M+34.1%
Q2 FY2024Jun 30, 2024$2.56M+16.1%
Q1 FY2024Mar 31, 2024$1.60M+27.4%
Q4 FY2023Dec 31, 2023$2.05M+285.0%
Q3 FY2023Sep 30, 2023$2.12M+89.9%
Q2 FY2023Jun 30, 2023$2.20M-67.7%
Q1 FY2023Mar 31, 2023$1.26M-69.3%
Q4 FY2022Dec 31, 2022$531.41K-88.1%
Q3 FY2022Sep 30, 2022$1.12M-81.4%
Q2 FY2022Jun 30, 2022$6.81M+2.4%
Q1 FY2022Mar 31, 2022$4.09M-39.5%
Q4 FY2021Dec 31, 2021$4.46M-52.2%
Q3 FY2021Sep 30, 2021$6.02M-31.3%
Q2 FY2021Jun 30, 2021$6.65M-37.8%
Q1 FY2021Mar 31, 2021$6.76M-25.6%
Q4 FY2020Dec 31, 2020$9.33M+16.0%
Q3 FY2020Sep 30, 2020$8.76M+78.4%
Q2 FY2020Jun 30, 2020$10.69M+147.6%
Q1 FY2020Mar 31, 2020$9.10M+147.3%
Q4 FY2019Dec 31, 2019$8.04M+83.0%
Q3 FY2019Sep 30, 2019$4.91M+112.8%
Q2 FY2019Jun 30, 2019$4.32M–
Q1 FY2019Mar 31, 2019$3.68M–
Q4 FY2018Dec 31, 2018$4.39M–
Q3 FY2018Sep 30, 2018$2.31M–

More Aprea Therapeutics figures

See a number that looks wrong?